

Publication

04/03/2020

COVID-19 Shows Need for Stronger Diagnostic IP Protection

Mike Harlin recently published an “Expert Analysis” article in *Law360* entitled “COVID-19 Shows Need for Stronger Diagnostic IP Protection.” In the article, Mike discusses Labrador Diagnostics LLC’s suit against test manufacturer BioFire LLC and its parent company bioMérieux SA for developing tests for COVID-19. Making the optics even worse, the patents were originally owned by Theranos, a testing company based on a massive fraud. The case illustrates the crucial role of the patent system in health care and the need for Congress to enact legislation to make patents more available for inventions related to diagnostic tests.

[Click here to read the article.](#)

The content above is based on information current at the time of its publication and may not reflect the most recent developments or guidance. Neal Gerber Eisenberg LLP provides this content for general informational purposes only. It does not constitute legal advice, and does not create an attorney-client relationship. You should seek advice from professional advisers with respect to your particular circumstances.

CLIENT SERVICES

Patents
Patent Opinions
Patent Prosecution
Patent Litigation
COVID-19 Insights

RELATED PEOPLE

Michael B. Harlin